⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CORT News
Corcept Therapeutics Inc.
Corcept to Present New Late-Breaking Data From Pivotal ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer at ESMO 2025
businesswire.com
CORT
FDA Files Corcept’s New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
businesswire.com
CORT